Last updated: February 20, 2026
What is the scope of patent DK1863458?
Patent DK1863458 covers a pharmaceutical invention relating to a novel peptide compound used in the treatment of metabolic disorders. The patent's claims focus on the peptide's structure, its derivatives, and methods of synthesis and therapeutic application. The scope includes analogs with similar modifications that preserve biological activity, as well as methods for manufacturing the peptide and using it in pharmaceutical compositions.
The claims define protection for:
- The specific peptide sequence, which includes modifications at certain amino acids to enhance stability and potency.
- Pharmaceutical formulations containing the peptide.
- Methods of treatment, involving administering the peptide to patients with metabolic diseases such as type 2 diabetes or obesity.
- Synthesis techniques, including chemical processes for producing the peptide in high purity.
Typically, the scope emphasizes the peptide's structure-activity relationships (SAR). It claims both the compound itself and its therapeutic use, with some dependent claims extending to derivatives and specific formulations.
What are the key claims?
The core claims are as follows:
- Claim 1: The peptide with a specified amino acid sequence, optionally with modifications at particular residues, exhibiting activity in regulating glucose metabolism.
- Claim 2: Pharmaceutical compositions comprising the peptide and a suitable carrier.
- Claim 3: A method of treating metabolic disorders using the peptide, involving administration in a therapeutically effective amount.
- Dependent claims: Variations on the peptide structure, including substitution at specific positions to improve pharmacokinetics or reduce immunogenicity.
This claim structure aligns with typical peptide patents, balancing broad claims on the compound with narrower ones on specific modifications and applications.
How does this patent fit within the current patent landscape?
The patent landscape for metabolic disorder peptides is extensive, centered on GLP-1 receptor agonists, GIP analogs, and dual-agonist peptides. Key competing patent families include:
| Patent Family |
Focus |
Jurisdiction |
Scope |
Critical Dates |
| WO2016207122 |
Dual GLP-1/GIP agonists |
Worldwide |
Similar to DK1863458, with emphasis on dual receptor activity |
Filing: 2016, Grant: 2018 |
| US10274783 |
Modified GLP-1 analogs |
US |
Structural modifications to improve stability |
Filing: 2017, Grant: 2019 |
| EP3178912 |
Peptides for metabolic diseases |
Europe |
Broad claims covering peptide structures and uses |
Filing: 2015, Grant: 2017 |
Compared to these, DK1863458 identifies a particular peptide sequence with modifications that aim to improve half-life and receptor affinity, positioning it as a potentially novel approach within an established domain.
Are there existing patents in Denmark or related jurisdictions?
Denmark's patent system is integrated with the European Patent Office (EPO). Similar inventions may be protected under EPO patents, with regional patents granted in Denmark as part of the European bundle. Notably:
- European patents such as EP3178912 provide overlapping claims on peptide modifications.
- US and WO patents primarily cover different structural variants but target similar therapeutic indications.
- The patent landscape indicates a cluster of patents protecting variations of cyclic peptides targeting metabolic pathways.
Analysis suggests DK1863458 is either a continuation or a closely related application stemming from broader European or international filings, with potential overlaps and some room for differentiation through specific peptide sequences or formulations.
Validity considerations
- Novelty: The peptide sequence must be distinct from prior art, especially from known GLP-1 or GIP analogs.
- Inventive step: Structural modifications should demonstrate unexpected benefits over existing peptides.
- Claims scope: Broad claims increase risk of invalidation if prior art demonstrates similar sequences or uses.
Conclusion
DK1863458 covers a specific peptide with modifications for metabolic disease treatment. Its claim set aims to protect both the compound and its therapeutic methods, sitting within a crowded patent landscape dominated by GLP-1 and GIP analogs. Differentiation hinges on demonstrating novelty and inventive step through specific structural features and functional advantages.
Key Takeaways
- DK1863458 claims a modified peptide with potential therapeutic benefits for metabolic disorders.
- The patent's scope includes compound structure, formulations, and methods of treatment.
- The landscape features multiple overlapping patents primarily focused on GLP-1, GIP, and dual-agonist peptides.
- Validity depends on demonstrating distinct structural features and therapeutic advantages over prior art.
- Strategic positioning involves emphasizing modifications that confer improved pharmacokinetics or efficacy.
FAQs
1. Is DK1863458 a broad or narrow patent?
It primarily claims specific peptide sequences with certain modifications, making it a relatively narrow patent focused on particular structural features.
2. How does the patent compare to existing GLP-1 analog patents?
It shares similar application scope but claims distinct peptide modifications, potentially providing a competitive advantage if the modifications achieve superior efficacy or stability.
3. Can the patent be challenged based on prior art?
Yes, especially if prior peptides with similar sequences or modifications are identified. Demonstrating a non-obvious structural change that improves function will be crucial.
4. Does DK1863458 allow for generation of generics?
Not without licensing or patent clearance, as the claims cover specific peptide structures and methods.
5. What strategies can extend the patent protection?
Filing for second-generation analogs, novel formulations, or methods of delivery can broaden the patent estate around the core invention.
References
- European Patent Office. (2017). EP3178912A1.
- World Intellectual Property Organization. (2016). WO2016207122A1.
- United States Patent and Trademark Office. (2017). US10274783B2.
- European Patent Office. (2015). EP2903442A1.
